Search
Silence Therapeutics PLC
SLNAdd to Watchlist
10.490USD
-1.130-9.72%
Close 07-31 16:00（ET）Quotes delayed by 15 min
495.49MMarket Cap
LossP/E TTM
More Details of Silence Therapeutics PLC Company
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Silence Therapeutics PLC Info
Ticker SymbolSLN
Company nameSilence Therapeutics PLC
IPO dateJan 05, 2010
CEOTooman (Craig A)
Number of employees116
Security typeDepository Receipt
Fiscal year-endJan 05
Address72 Hammersmith Road
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeW14 8TH
Phone442034576900
Websitehttps://www.silence-therapeutics.com/
Ticker SymbolSLN
IPO dateJan 05, 2010
CEOTooman (Craig A)
Company Executives of Silence Therapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
FAQs
Who are the top five shareholders of Silence Therapeutics PLC?
The top five shareholders of Silence Therapeutics PLC are: Mr. David Jakob (Dave) Lemus, CPA
How many institutions hold shares of Silence Therapeutics PLC (SLN)?
As of 2026Q1, 147 institutions hold shares of Silence Therapeutics PLC, with a combined market value of approximately 19.17M, accounting for 40.59% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -12508865.00.